Operating Segments (Tables)

6 Months Ended

Jun. 30, 2026

Operating Segments

Schedule of operating segments

The following table presents the revenues, significant expenses, and operating results of the Company's reportable segments for the three months ended June 30, 2026:

Specialized
BioTherapeutics

Public Health
Solutions

Corporate

Adjustments

Consolidated

Revenues

$

-

$

-

$

-

$

-

$

-

Cost of revenues

-

-

-

-

-

Gross profit

-

-

-

-

-

Significant expenses:

Research and development

831,614

2,745

99,726

40,006

974,091

General and administrative

-

-

1,048,309

77,063

1,125,372

Adjusted loss from operations

(831,614)

(2,745)

(1,148,035)

(117,069)

(2,099,463)

Share-based compensation

39,239

-

76,733

(115,972)

-

Depreciation and amortization

658

109

330

(1,097)

-

Loss from operations

(871,511)

(2,854)

(1,225,098)

-

(2,099,463)

Other income, net

-

-

112,109

-

112,109

Net loss before income taxes

$

(871,511)

$

(2,854)

$

(1,112,989)

$

-

$

(1,987,354)

The following table presents the revenues, significant expenses, and operating results of the Company's reportable segments for the three months ended June 30, 2025:


		Specialized BioTherapeutics			Public Health Solutions			Corporate			Adjustments			Consolidated
Revenues		$	-		$	-		$	-		$	-		$	-
Cost of revenues			-			-			-			-			-
Gross profit			-			-			-			-			-
Significant expenses:
Research and development			1,523,099			3,332			122,764			27,819			1,677,014
General and administrative			-			-			1,014,468			72,397			1,086,865
Adjusted loss from operations			(1,523,099)			(3,332)			(1,137,232)			(100,216)			(2,763,879)
Share-based compensation			26,487			839			72,187			(99,513)			-
Depreciation and amortization			423			70			210			(703)			-
Loss from operations			(1,550,009)			(4,241)			(1,209,629)			-			(2,763,879)
Other income, net			-			-			61,903			-			61,903
Net loss before income taxes		$	(1,550,009)		$	(4,241)		$	(1,147,726)		$	-		$	(2,701,976)

The following table presents the revenues, significant expenses, and operating results of the Company's reportable segments for the six months ended June 30, 2026:

Specialized
BioTherapeutics

Public Health
Solutions

Corporate

Adjustments

Consolidated

Revenues

$

-

$

-

$

-

$

-

$

-

Cost of revenues

-

-

-

-

-

Gross profit

-

-

-

-

-

Significant expenses:

Research and development

2,476,711

5,295

189,140

85,245

2,756,391

General and administrative

-

-

2,073,780

154,130

2,227,910

Adjusted loss from operations

(2,476,711)

(5,295)

(2,262,920)

(239,375)

(4,984,301)

Share-based compensation

83,709

-

153,471

(237,180)

-

Depreciation and amortization

1,317

219

659

(2,195)

-

Loss from operations

(2,561,737)

(5,514)

(2,417,050)

-

(4,984,301)

Other income, net

-

-

171,982

-

171,982

Net loss before income taxes

$

(2,561,737)

$

(5,514)

$

(2,245,068)

$

-

$

(4,812,319)

The following table presents the revenues, significant expenses, and operating results of the Company's reportable segments for the six months ended June 30, 2025:


		Specialized BioTherapeutics			Public Health Solutions			Corporate			Adjustments			Consolidated
Revenues		$	-		$	-		$	-		$	-		$	-
Cost of revenues			-			-			-			-			-
Gross profit			-			-			-			-			-
Significant expenses:
Research and development			3,273,701			61,667			227,754			55,572			3,618,694
General and administrative			-			-			2,062,842			108,851			2,171,693
Adjusted loss from operations			(3,273,701)			(61,667)			(2,290,596)			(164,423)			(5,790,387)
Share-based compensation			52,975			1,679			108,458			(163,112)			-
Depreciation and amortization			787			131			393			(1,311)			-
Loss from operations			(3,327,463)			(63,477)			(2,399,447)			-			(5,790,387)
Other income, net			-			-			137,143			-			137,143
Net loss before income taxes		$	(3,327,463)		$	(63,477)		$	(2,262,304)		$	-		$	(5,653,244)

Reconciliation to Consolidated Loss Before Income Taxes

The following table provides a reconciliation of total segment loss to consolidated loss before income taxes for the three months ended June 30:


		2026			2025
Loss from operations - reportable segments		$	(874,365)		$	(1,554,250)
Loss from operations - corporate			(1,225,098)			(1,209,629)
Interest income, net			53,598			69,823
Other income (expense), net			58,511			(7,920)
Net loss before income taxes		$	(1,987,354)		$	(2,701,976)

The following table provides a reconciliation of total segment loss to consolidated loss before income taxes for the six months ended June 30:


		2026			2025
Loss from operations - reportable segments		$	(2,567,251)		$	(3,390,940)
Loss from operations - corporate			(2,417,050)			(2,399,447)
Interest income, net			114,987			145,851
Other income (expense), net			56,995			(8,708)
Net loss before income taxes		$	(4,812,319)		$	(5,653,244)

Segment Assets

The Company’s total assets by segment as of June 30, 2026, are presented below:

Specialized BioTherapeutics

Public Health
Solutions

Total
Segments

Corporate

Consolidated

Total assets

$

242,676

$

2,192

$

244,868

$

10,254,602

$

10,499,470

The Company’s total assets by segment as of June 30, 2025, are presented below:


		Specialized BioTherapeutics			Public Health Solutions			Total Segments			Corporate			Consolidated
Total assets		$	112,342		$	2,705		$	115,047		$	5,645,600		$	5,760,647